Skip to search formSkip to main contentSkip to account menu

AZD3514

Known as: Androgen Receptor Downregulator AZD3514, SARD AZD3514 
An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ObjectivesTo investigate the relationships between interferon alpha (IFNα) and the clinical and serological phenotype of patients… 
2018
2018
The androgen receptor (AR) is expressed in 60%–70% of breast cancers regardless of estrogen receptor status, and has been… 
2016
2016
BackgroundThe continual reassessment method (CRM) requires an underlying model of the dose-toxicity relationship (“prior skeleton… 
2016
2016
La voie de signalisation du recepteur des androgenes (RA) reste une cible therapeutique privilegiee dans les cancers de la… 
2015
2015
SummaryBackground AZD3514 is a first-in-class, orally bio-available, androgen-dependent and -independent androgen receptor… 
Highly Cited
2013
Highly Cited
2013
Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after… 
2013
2013
4511 Background: AZD3514 is a first in class, orally bio-available drug that inhibits androgen-dependent and –independent… 
2012
2012
The androgen receptor (AR), an important molecular target in the aetiology and progression of prostate cancer, has been found…